EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy

Akram I Ahmad, Samita Garg, Jeffrey Jacobs, Zaid Ansari, Tasneem Jamal Al-Din, Ashraf Almomani, Sara Valencia, John Vargo, Arjun Chatterjee, Hassan Siddiki, Liang Hong, Michael A Nicolas und 2 weitere

JAMA Internal Medicine · 01.05.2026 · 186 (5) · 578

DOI: 10.1001/jamainternmed.2026.0027 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.05.2026. Verfasst von Akram I Ahmad und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Cleveland Clinic Florida, Weston. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Gastric Inhibitory Polypeptide, Endoscopy, Gastrointestinal. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are known to increase the risk of retained gastric contents. High-quality data are lacking to guide periprocedure management of GLP-1 and GIP agonists.

Objective

To compare the risk of clinically significant residual gastric volume (RGV) in patients who continue vs hold 1 dose of weekly or daily GLP-1 and GIP agonists prior to sedation. Design, Setting, and Participants This randomized, single-masked clinical trial conducted at 2 large tertiary referral centers in the US included patients undergoing elective upper endoscopy (EGD) who were receiving GLP-1 or GLP-1/GIP agonists between July 2024 and May 2025. Eligible participants were adults aged 18 years or older, scheduled for EGD with or without colonoscopy, under moderate sedation or monitored anesthesia care, and taking a stable dose of a GLP-1 or GLP-1/GIP agonist for at least 1 month. Exclusion criteria were prior foregut surgery, achalasia, documented gastroparesis, RGV on previous endoscopy, gastric outlet obstruction, planned general anesthesia, or recent opioid use. Data were analyzed May 2025.

Intervention

Participants were randomized to either continue their medication or hold 1 dose prior to the procedure. Main Outcomes and Measures Clinically significant RGV, a composite of gastric contents that (1) precludes endoscopic examination, (2) requires premature termination or endotracheal intubation, and/or (3) results in an aspiration event that necessitates extended observation or monitoring, unplanned therapeutics, or hospital admission.

Results

There were 60 patients (32 holding 1 dose, 28 continuing medication) in the preplanned interim analysis (median [IQR] age, 62.5 [55.5-67.5] years; 30 female [50.0%]). Clinically significant RGV occurred in 3.1% in the hold group vs 25.0% in the continue group (absolute difference, 21.9% [90% CI, 7.0%-36.7%]; P = .003). The trial was terminated early as risk exceeded the preestablished O’Brien-Fleming stopping boundary. In the EGD-only subgroup (35 patients), clinically significant RGV occurred in 46.7% in the continue vs 5.0% in the hold groups (absolute difference, 41.7% [90% CI, 17.9%-65.4%]; P = .001). In the EGD plus colonoscopy subgroup (25 patients), who were on clear liquids the day prior, no patients had clinically significant RGV. Conclusions and Relevance This randomized clinical trial found that continuing GLP-1 or GIP agonist in the preprocedural period increased clinically significant RGV but did not increase the risk of other adverse events. Clear liquids the day prior to the procedure may mitigate the risk of clinically significant RGV regardless of GLP-1/GIP use. Trial Registration ClinicalTrials.gov Identifier: NCT06533527

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Gastric Inhibitory PolypeptideEndoscopy, GastrointestinalHumansFemaleMaleMiddle AgedSingle-Blind MethodAgedAdult

Substanzen

Glucagon-Like Peptide 1Gastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • Department of Gastroenterology, Cleveland Clinic Florida, Weston.
  • Department of Gastroenterology, Cleveland Clinic, Cleveland, Ohio.
  • Department of Anesthesiology, Cleveland Clinic Florida, Weston.
  • Department of Gastroenterology, University of Missouri, Columbia.
  • Department of Medicine, MetroHealth Medical System, Cleveland, Ohio.
  • Department of Clinical Research, Cleveland Clinic Florida, Weston.

Zitieren

APA

Ahmad, A. I., Garg, S., Jacobs, J., Ansari, Z., Al-Din, T. J., Almomani, A., Valencia, S., Vargo, J., Chatterjee, A., Siddiki, H., Hong, L., Nicolas, M. A., Miller, A., & Shah, T. (2026). Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy. JAMA Internal Medicine, 186(5), 578. https://doi.org/10.1001/jamainternmed.2026.0027

Vancouver

Ahmad AI, Garg S, Jacobs J, Ansari Z, Al-Din TJ, Almomani A, et al. Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy. JAMA Internal Medicine. 2026;186(5):578. doi:10.1001/jamainternmed.2026.0027

BibTeX
@article{Ahmad2026,
  author = {Ahmad, Akram I and Garg, Samita and Jacobs, Jeffrey and Ansari, Zaid and Al-Din, Tasneem Jamal and Almomani, Ashraf and Valencia, Sara and Vargo, John and Chatterjee, Arjun and Siddiki, Hassan and Hong, Liang and Nicolas, Michael A and Miller, Alaina and Shah, Tilak},
  title = {Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy},
  journal = {JAMA Internal Medicine},
  year = {2026},
  volume = {186},
  number = {5},
  pages = {578},
  doi = {10.1001/jamainternmed.2026.0027}
}
Kostenlos starten →